首页 > 最新文献

中华胃肠外科杂志最新文献

英文 中文
[Artificial intelligence empowers functional preservation and safety guarantee in laparoscopic colorectal surgery]. 【人工智能助力腹腔镜结直肠手术功能保存与安全保障】
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250318-00106
Z Sun, Y Xiao

Transabdominal and transanal endoscopic approaches have become mainstream in colorectal surgery. With the substantial improvement in survival outcomes for colorectal cancer patients, a growing number of colorectal surgeons are increasingly focusing on enhancing postoperative quality of life, prioritizing functional preservation, especially the intraoperative preservation of pelvic autonomic nerves. Recently, with the gradual deepening of artificial intelligence (AI) applications in the medical field, colorectal surgeons have begun exploring its implementation in colorectal surgery. Current achievements primarily involve the identification and protection of nerves and organs. However, most AI applications remain at preclinical exploration stages, limiting their clinical application. Furthermore, AI faces challenges in recognizing blood vessels with significant deformation and movement. Thus, the precise real-time navigation and protection of blood vessels during surgery have yet to be achieved. Therefore, future developments in this field should focus on resolving issues such as non-rigid registration, real-time calibration etc., thereby deepening the application of AI in functional preservation and surgical safety assurance during laparoscopic colorectal surgery.

经腹和经肛内镜入路已成为结直肠手术的主流。随着结直肠癌患者生存结局的显著改善,越来越多的结直肠外科医生越来越重视提高术后生活质量,优先考虑功能的保存,尤其是术中盆腔自主神经的保存。近年来,随着人工智能(AI)在医疗领域应用的逐步深入,结直肠外科医生开始探索其在结直肠手术中的应用。目前的成果主要涉及神经和器官的识别和保护。然而,大多数人工智能应用仍处于临床前探索阶段,限制了其临床应用。此外,人工智能在识别具有明显变形和运动的血管方面面临挑战。因此,手术中血管的精确实时导航和保护尚未实现。因此,未来该领域的发展应重点解决非刚性配准、实时校准等问题,从而深化人工智能在腹腔镜结直肠手术中功能保存和手术安全保障方面的应用。
{"title":"[Artificial intelligence empowers functional preservation and safety guarantee in laparoscopic colorectal surgery].","authors":"Z Sun, Y Xiao","doi":"10.3760/cma.j.cn441530-20250318-00106","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20250318-00106","url":null,"abstract":"<p><p>Transabdominal and transanal endoscopic approaches have become mainstream in colorectal surgery. With the substantial improvement in survival outcomes for colorectal cancer patients, a growing number of colorectal surgeons are increasingly focusing on enhancing postoperative quality of life, prioritizing functional preservation, especially the intraoperative preservation of pelvic autonomic nerves. Recently, with the gradual deepening of artificial intelligence (AI) applications in the medical field, colorectal surgeons have begun exploring its implementation in colorectal surgery. Current achievements primarily involve the identification and protection of nerves and organs. However, most AI applications remain at preclinical exploration stages, limiting their clinical application. Furthermore, AI faces challenges in recognizing blood vessels with significant deformation and movement. Thus, the precise real-time navigation and protection of blood vessels during surgery have yet to be achieved. Therefore, future developments in this field should focus on resolving issues such as non-rigid registration, real-time calibration etc., thereby deepening the application of AI in functional preservation and surgical safety assurance during laparoscopic colorectal surgery.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"615-618"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer]. [摄像机倒置技术在腹腔镜下中低位直肠癌保括约肌手术中的应用]
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20240901-00300
R Hou, G B Li, X Y Qiu, X Zhang, G L Lin

Objective: To explore the application of the camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer. Methods: A retrospective study with historical controls was conducted on patients with non-metastatic mid to low rectal cancer which received laparoscopic total mesorectal excision at Peking Union Medical College Hospital from January 2019 to June 2024. The experimental group (2021.7-2024.6) utilized the camera inversion technique (rotating the lens 180° to position the bevel upward and switching the system to reverse display mode for improved visualization and operative angles) during key surgical steps (such as intraoperative mobilization of the mid-to-lower rectum and anastomosis), while the control group (2019.1-2021.6) did not. Clinical data and surgical videos were collected to analyze indicators like operative time, blood loss, mesorectal integrity, surgical complications, and postoperative hospital stay. Results: A total of 624 patients with non-metastatic mid to low rectal cancer were included, including 412 males and 212 females, with an average age of 59.8 years and an average tumor distance of 5.6 cm from the anal verge. The experimental group comprised 301 patients, while the control group had 323 patients.The proportion of abdominal ISR (intersphincteric resection) was significantly higher in the experimental group [19.3% (58/301) vs. 10.2%(33/323), χ2=10.140, P=0.001], with a reduction in operative time [(161.8±67.8) minutes vs. (150.2±68.5) minutes, t=2.134, P=0.033] and a decrease in postoperative hospital stay [(7.8±2.1) days vs. (8.3±3.4) days, t=2.003, P=0.046]. The experimental group also demonstrated advantages in intraoperative blood loss, mesorectal integrity rate, and postoperative complications such as urinary retention, though these differences were not statistically significant (all P>0.05). Conclusion: In laparoscopic surgery for mid to low rectal cancer, using camera inversion technique during distal rectum dissection and transanal anastomosis can provide better surgical field exposure, facilitate precise operations within the correct anatomical plane, and minimize collateral damage. The camera inversion technique is safe and effective.

目的:探讨摄像机倒置技术在腹腔镜下中低位直肠癌保括约肌手术中的应用。方法:对2019年1月至2024年6月在北京协和医院行腹腔镜全肠系膜切除术的非转移性中低位直肠癌患者进行回顾性研究。实验组(2021.7-2024.6)在手术的关键步骤(如术中直肠中下段的活动和吻合)中使用了相机反转技术(旋转镜头180°使斜角向上定位,并切换系统到反向显示模式以提高视觉效果和手术角度),而对照组(2019.1-2021.6)没有使用。收集临床资料和手术录像,分析手术时间、出血量、肠系膜完整性、手术并发症、术后住院时间等指标。结果:共纳入非转移性中低位直肠癌患者624例,其中男性412例,女性212例,平均年龄59.8岁,肿瘤距肛缘平均距离5.6 cm。实验组301例,对照组323例。实验组腹部ISR(括括肌间切除术)比例明显高于对照组[19.3%(58/301)比10.2%(33/323),χ2=10.140, P=0.001],手术时间缩短[(161.8±67.8)分钟比(150.2±68.5)分钟,t=2.134, P=0.033],术后住院时间缩短[(7.8±2.1)天比(8.3±3.4)天,t=2.003, P=0.046]。实验组在术中出血量、直肠系膜完整性率、术后尿潴留等并发症方面也有优势,但差异无统计学意义(P < 0.05)。结论:在腹腔镜下中低位直肠癌手术中,在直肠远端解剖及经肛门吻合术中使用相机倒置技术,可以提供更好的手术野暴露,便于在正确的解剖平面内精确操作,减少附带损伤。相机反演技术是安全有效的。
{"title":"[Camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer].","authors":"R Hou, G B Li, X Y Qiu, X Zhang, G L Lin","doi":"10.3760/cma.j.cn441530-20240901-00300","DOIUrl":"10.3760/cma.j.cn441530-20240901-00300","url":null,"abstract":"<p><p><b>Objective:</b> To explore the application of the camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer. <b>Methods:</b> A retrospective study with historical controls was conducted on patients with non-metastatic mid to low rectal cancer which received laparoscopic total mesorectal excision at Peking Union Medical College Hospital from January 2019 to June 2024. The experimental group (2021.7-2024.6) utilized the camera inversion technique (rotating the lens 180° to position the bevel upward and switching the system to reverse display mode for improved visualization and operative angles) during key surgical steps (such as intraoperative mobilization of the mid-to-lower rectum and anastomosis), while the control group (2019.1-2021.6) did not. Clinical data and surgical videos were collected to analyze indicators like operative time, blood loss, mesorectal integrity, surgical complications, and postoperative hospital stay. <b>Results:</b> A total of 624 patients with non-metastatic mid to low rectal cancer were included, including 412 males and 212 females, with an average age of 59.8 years and an average tumor distance of 5.6 cm from the anal verge. The experimental group comprised 301 patients, while the control group had 323 patients.The proportion of abdominal ISR (intersphincteric resection) was significantly higher in the experimental group [19.3% (58/301) vs. 10.2%(33/323), χ<sup>2</sup>=10.140, <i>P</i>=0.001], with a reduction in operative time [(161.8±67.8) minutes vs. (150.2±68.5) minutes, <i>t</i>=2.134, <i>P</i>=0.033] and a decrease in postoperative hospital stay [(7.8±2.1) days vs. (8.3±3.4) days, <i>t</i>=2.003, <i>P</i>=0.046]. The experimental group also demonstrated advantages in intraoperative blood loss, mesorectal integrity rate, and postoperative complications such as urinary retention, though these differences were not statistically significant (all <i>P</i>>0.05). <b>Conclusion:</b> In laparoscopic surgery for mid to low rectal cancer, using camera inversion technique during distal rectum dissection and transanal anastomosis can provide better surgical field exposure, facilitate precise operations within the correct anatomical plane, and minimize collateral damage. The camera inversion technique is safe and effective.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"679-683"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pathogenesis, risk factors and treatment of low anterior resection syndrome after colon surgery]. 【结肠手术后低位前切除术综合征的发病机制、危险因素及治疗】。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250317-00105
Y C Guo, H X Zhao, Q Wang

Low anterior resection syndrome (LARS) is a series of symptoms of intestinal dysfunction, and its research is mainly focused on patients with low rectal surgery. However, with the deepening understanding of postoperative LARS, surgeons found that LARS not only exists among patients who have undergone low anterior resection of rectum, but also plagues a considerable number of patients who have undergone non-rectal (mainly colon) surgeries. This article aims to elaborate on the incidence and treatment of LARS after colon surgery. Through a comprehensive analysis of relevant studies, it is found that the incidence of LARS after colon surgery is approximately 20%-30%, and the incidence is relatively higher in patients undergoing right hemicolectomy. Its pathogenesis is related to multiple factors, including surgical methods, resection range, changes in intestinal flora, patient age, gender, and underlying diseases. Treatment methods include conservative treatments such as dietary adjustment, drug therapy, transanal irrigation, and rehabilitation training. Single treatment methods have limited effect, while comprehensive treatment can effectively improve patients' symptoms and quality of life. The current LARS scoring system has not been effectively verified in the application after colon cancer surgery, and it is necessary to develop a more targeted scoring system.

低位前切综合征(LARS)是一系列肠道功能障碍的症状,其研究主要集中在低位直肠手术患者。然而,随着对术后LARS认识的加深,外科医生发现LARS不仅存在于低位直肠前切除术的患者中,也困扰着相当一部分非直肠(以结肠为主)手术的患者。本文旨在阐述结肠手术后LARS的发生率和治疗方法。通过综合分析相关研究发现,结肠手术后LARS的发生率约为20%-30%,其中右半结肠切除术患者的发生率相对较高。其发病机制与多种因素有关,包括手术方式、切除范围、肠道菌群变化、患者年龄、性别、基础疾病等。治疗方法包括保守治疗,如饮食调整、药物治疗、经肛冲洗、康复训练等。单一治疗方法效果有限,综合治疗可有效改善患者症状和生活质量。目前的LARS评分系统在结肠癌手术后的应用中尚未得到有效验证,有必要开发更有针对性的评分系统。
{"title":"[Pathogenesis, risk factors and treatment of low anterior resection syndrome after colon surgery].","authors":"Y C Guo, H X Zhao, Q Wang","doi":"10.3760/cma.j.cn441530-20250317-00105","DOIUrl":"10.3760/cma.j.cn441530-20250317-00105","url":null,"abstract":"<p><p>Low anterior resection syndrome (LARS) is a series of symptoms of intestinal dysfunction, and its research is mainly focused on patients with low rectal surgery. However, with the deepening understanding of postoperative LARS, surgeons found that LARS not only exists among patients who have undergone low anterior resection of rectum, but also plagues a considerable number of patients who have undergone non-rectal (mainly colon) surgeries. This article aims to elaborate on the incidence and treatment of LARS after colon surgery. Through a comprehensive analysis of relevant studies, it is found that the incidence of LARS after colon surgery is approximately 20%-30%, and the incidence is relatively higher in patients undergoing right hemicolectomy. Its pathogenesis is related to multiple factors, including surgical methods, resection range, changes in intestinal flora, patient age, gender, and underlying diseases. Treatment methods include conservative treatments such as dietary adjustment, drug therapy, transanal irrigation, and rehabilitation training. Single treatment methods have limited effect, while comprehensive treatment can effectively improve patients' symptoms and quality of life. The current LARS scoring system has not been effectively verified in the application after colon cancer surgery, and it is necessary to develop a more targeted scoring system.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"633-638"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Application of anorectal manometry in diagnosis and treatment of low anterior resection syndrome]. [肛肠测压在前低位切除综合征诊治中的应用]。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250310-00095
J Q Kang, Z Zhang

With the advancement of rectal cancer surgery, low anterior resection syndrome (LARS) has emerged as a significant issue impacting the postoperative quality of life for patients. Anorectal manometry (ARM), an essential diagnostic tool, possesses principles and methodologies that are crucial for assessing anorectal function. In the context of LARS diagnosis, ARM plays a pivotal role by providing objective evidence for clinical evaluations. Concurrently, the implications and efficacy of this technology in treatment are gaining increasing attention. Nonetheless, several challenges remain regarding its current application. Through an analysis of existing research, this article aims to elucidate the value of ARM in both the diagnosis and treatment of LARS, with the ultimate goal of enhancing the diagnostic and therapeutic approaches to LARS and improving patients' quality of life.

随着直肠癌手术技术的进步,低位前切除术综合征(LARS)已成为影响患者术后生活质量的重要问题。肛肠测压(ARM)是一种重要的诊断工具,其原理和方法对评估肛肠功能至关重要。在LARS诊断中,ARM为临床评价提供客观证据,发挥着关键作用。同时,这项技术在治疗中的意义和功效也越来越受到关注。尽管如此,目前的应用仍然存在一些挑战。本文通过对现有研究的分析,旨在阐明ARM在LARS的诊断和治疗中的价值,最终目的是提高LARS的诊断和治疗方法,提高患者的生活质量。
{"title":"[Application of anorectal manometry in diagnosis and treatment of low anterior resection syndrome].","authors":"J Q Kang, Z Zhang","doi":"10.3760/cma.j.cn441530-20250310-00095","DOIUrl":"10.3760/cma.j.cn441530-20250310-00095","url":null,"abstract":"<p><p>With the advancement of rectal cancer surgery, low anterior resection syndrome (LARS) has emerged as a significant issue impacting the postoperative quality of life for patients. Anorectal manometry (ARM), an essential diagnostic tool, possesses principles and methodologies that are crucial for assessing anorectal function. In the context of LARS diagnosis, ARM plays a pivotal role by providing objective evidence for clinical evaluations. Concurrently, the implications and efficacy of this technology in treatment are gaining increasing attention. Nonetheless, several challenges remain regarding its current application. Through an analysis of existing research, this article aims to elucidate the value of ARM in both the diagnosis and treatment of LARS, with the ultimate goal of enhancing the diagnostic and therapeutic approaches to LARS and improving patients' quality of life.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"639-643"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Expert consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)]. [直肠癌手术中盆腔器官功能保护专家共识(2025版)]。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250410-00153

With the development of surgical techniques, adjuvant therapy and neoadjuvant therapy, the survival time of rectal cancer patients after surgery has been significantly improved, but organ dysfunction is still an important problem affecting the quality of life of patients after surgery. With the continuous deepening of clinical research and practice and the updating of relevant theories, more detailed and reliable evidence-based medical evidence has been accumulated in the field of pelvic organ function protection in rectal cancer surgery, and has been continuously verified in the clinical real world at home and abroad. In order to further improve the awareness of domestic physicians on the protection of organ function during the treatment of rectal cancer, standardize the evaluation methods and surgical methods, reduce the incidence of organ dysfunction, and thus improve the quality of life of patients, Society of Colon & Rectal Surgeons of Chinese College of Surgeons of Chinese Medical Doctor Association, Section of Colorectal Surgery of Branch of Surgery of Chinese Medical Association, National Health Commission Capacity Building and Continuing Education Center Colorectal Surgery Committee, and Colorectal and Anal Function Surgeons Committee of China Sexology Association organized the discussion among relevant experts. On the basis of the 2021 edition of the Chinese Expert Consensus on the Protection of Pelvic Organ Function in Rectal Cancer Surgery, the recent evidence-based medical evidence was analyzed and summarized, and the definition, risk factors, evaluation methods, prevention and other issues of organ dysfunction after rectal cancer surgery were analyzed with reference to relevant domestic and foreign studies and combined with clinical practice. Proposed the diagnosis, evaluation and treatment of pelvic organ dysfunction in rectal cancer surgery, and finally formed the "Chinese expert Consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)".

随着手术技术、辅助治疗和新辅助治疗的发展,直肠癌患者术后生存时间明显提高,但器官功能障碍仍是影响患者术后生活质量的重要问题。随着临床研究与实践的不断深入和相关理论的更新,在直肠癌手术盆腔器官功能保护领域积累了更加详细可靠的循证医学证据,并在国内外临床现实世界中不断得到验证。为进一步提高国内医师对直肠癌治疗过程中保护脏器功能的认识,规范评估方法和手术方法,减少脏器功能障碍的发生率,从而提高患者的生活质量,中华医师协会中国外科医师学会结直肠外科分会、中华医学会外科学分会结直肠外科分会、国家卫健委能力建设与继续教育中心结直肠外科专业委员会、中国性学协会结直肠与肛门功能外科专业委员会组织了相关专家的讨论。以2021版《中国直肠癌手术盆腔脏器功能保护专家共识》为基础,分析总结近期循证医学证据,参考国内外相关研究,结合临床实践,分析直肠癌手术后脏器功能障碍的定义、危险因素、评价方法、预防等问题。提出了直肠癌手术中盆腔器官功能障碍的诊断、评价和治疗,最终形成了《直肠癌手术中盆腔器官功能保护中国专家共识(2025版)》。
{"title":"[Expert consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)].","authors":"","doi":"10.3760/cma.j.cn441530-20250410-00153","DOIUrl":"10.3760/cma.j.cn441530-20250410-00153","url":null,"abstract":"<p><p>With the development of surgical techniques, adjuvant therapy and neoadjuvant therapy, the survival time of rectal cancer patients after surgery has been significantly improved, but organ dysfunction is still an important problem affecting the quality of life of patients after surgery. With the continuous deepening of clinical research and practice and the updating of relevant theories, more detailed and reliable evidence-based medical evidence has been accumulated in the field of pelvic organ function protection in rectal cancer surgery, and has been continuously verified in the clinical real world at home and abroad. In order to further improve the awareness of domestic physicians on the protection of organ function during the treatment of rectal cancer, standardize the evaluation methods and surgical methods, reduce the incidence of organ dysfunction, and thus improve the quality of life of patients, Society of Colon & Rectal Surgeons of Chinese College of Surgeons of Chinese Medical Doctor Association, Section of Colorectal Surgery of Branch of Surgery of Chinese Medical Association, National Health Commission Capacity Building and Continuing Education Center Colorectal Surgery Committee, and Colorectal and Anal Function Surgeons Committee of China Sexology Association organized the discussion among relevant experts. On the basis of the 2021 edition of the Chinese Expert Consensus on the Protection of Pelvic Organ Function in Rectal Cancer Surgery, the recent evidence-based medical evidence was analyzed and summarized, and the definition, risk factors, evaluation methods, prevention and other issues of organ dysfunction after rectal cancer surgery were analyzed with reference to relevant domestic and foreign studies and combined with clinical practice. Proposed the diagnosis, evaluation and treatment of pelvic organ dysfunction in rectal cancer surgery, and finally formed the \"Chinese expert Consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)\".</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"575-586"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparative study of clinical characteristics and prognosis between early- and late-onset rectal cancer]. 【早、晚发性直肠癌临床特点及预后的比较研究】。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20241209-00400
H P Hong, A Huang, J Y Shi, J Gu

Objective: To investigate the differences in clinical characteristics and prognosis between early- and late-onset rectal cancer (EORC and LORC, respectively), and to analyze the adverse factors affecting outcomes in EORC patients. Methods: This retrospective cohort and propensity score matching (PSM) study examined 904 rectal cancer patients who underwent radical resection at Peking University Shougang Hospital between 2017 and 2022. Prior to comparison, patients in the EORC group (<50 years old) and LORC group (≥50 years old) were matched at a 1:2 ratio to control for the following confounders: sex; neoadjuvant therapy; T, N, and M stage; and adjuvant treatment. Cox regression was used to identify independent risk factors for poor overall and progression-free survival (OS and PFS, respectively). Restricted cubic splines were used to analyze the association between age and clinical outcome. Results: A total of 199 EORC and 705 LORC patients were included for analysis. Prior to PSM, the proportions of patients with stage T4 [27.6%(55/199) vs.12.9%(91/705),χ2=30.12,P<0.001] and M1 disease [24.6%(49/199) vs. 15.7% (111/705),χ2=8.40,P=0.004], and the proportions of patients who received neoadjuvant [79.9% (159/199) vs. 62.3%(439/705), χ2=21.54, P<0.001] and adjuvant therapy [62.8%(125/199) vs. 50.8% (358/705), χ2=9.03, P=0.003] were significantly higher in the EORC group. Mean OS (57.8 vs. 51.9 months; P=0.011) and PFS (53.6 vs. 44.5 months; P=0.001) were also significantly longer in the LORC group. However, after PSM, the intergroup differences in OS and PFS were not significant (P=0.450 and 0.180, respectively). Multivariate Cox regression in the EORC cohort identified carcinoembryonic antigen concentration ≥5 μg/L [hazard ratio (HR), 3.79; 95% confidence interval (CI), 1.34-10.69; P=0.012] and presence of perineural invasion (HR, 7.27; 95%CI, 1.77-29.88; P=0.006) as independent risk factors for overall mortality; the only independent risk factor for cancer progression was carcinoembryonic antigen concentration ≥5 μg/L (HR, 2.56; 95%CI, 1.06-6.17; P=0.037). Restricted cubic spline analysis showed a U-shaped relationship between age and clinical outcome. After PSM, OS and PFS did not show a significant association with age in the < 60 years old group. Conclusion: Compared with LORC, EORC is more likely to be diagnosed at a later stage and has a worse outcome. Early diagnosis and timely treatment improve outcome in EORC patients.

目的:探讨早、晚发性直肠癌(分别为EORC和LORC)的临床特征及预后差异,并分析影响EORC患者预后的不良因素。方法:采用回顾性队列和倾向评分匹配(PSM)研究,对2017年至2022年在北京大学首钢医院接受根治性切除术的904例直肠癌患者进行分析。结果:共纳入199例EORC和705例LORC患者进行分析。PSM前,EORC组T4期患者比例[27.6%(55/199)vs.12.9%(91/705),χ2=30.12,P2=8.40,P=0.004]和接受新辅助治疗的患者比例[79.9% (159/199)vs. 62.3%(439/705), χ2=21.54, P2=9.03, P=0.003]均显著高于PSM组。平均OS (57.8 vs. 51.9个月;P=0.011)和PFS (53.6 vs 44.5个月;P=0.001),在LORC组中也明显更长。而PSM后,OS和PFS组间差异无统计学意义(P分别为0.450和0.180)。多因素Cox回归在EORC队列中发现癌胚抗原浓度≥5 μg/L[危险比(HR), 3.79;95%置信区间(CI), 1.34-10.69;P=0.012]和有无神经周围侵犯(HR, 7.27;95%置信区间,1.77 - -29.88;P=0.006)是总死亡率的独立危险因素;癌胚抗原浓度≥5 μg/L是肿瘤进展的唯一独立危险因素(HR, 2.56;95%置信区间,1.06 - -6.17;P = 0.037)。限制三次样条分析显示年龄与临床结果呈u型关系。PSM后,< 60岁组的OS和PFS与年龄无显著相关性。结论:与LORC相比,EORC更易被诊断为晚期,预后较差。早期诊断和及时治疗可改善EORC患者的预后。
{"title":"[Comparative study of clinical characteristics and prognosis between early- and late-onset rectal cancer].","authors":"H P Hong, A Huang, J Y Shi, J Gu","doi":"10.3760/cma.j.cn441530-20241209-00400","DOIUrl":"10.3760/cma.j.cn441530-20241209-00400","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the differences in clinical characteristics and prognosis between early- and late-onset rectal cancer (EORC and LORC, respectively), and to analyze the adverse factors affecting outcomes in EORC patients. <b>Methods:</b> This retrospective cohort and propensity score matching (PSM) study examined 904 rectal cancer patients who underwent radical resection at Peking University Shougang Hospital between 2017 and 2022. Prior to comparison, patients in the EORC group (<50 years old) and LORC group (≥50 years old) were matched at a 1:2 ratio to control for the following confounders: sex; neoadjuvant therapy; T, N, and M stage; and adjuvant treatment. Cox regression was used to identify independent risk factors for poor overall and progression-free survival (OS and PFS, respectively). Restricted cubic splines were used to analyze the association between age and clinical outcome. <b>Results:</b> A total of 199 EORC and 705 LORC patients were included for analysis. Prior to PSM, the proportions of patients with stage T4 [27.6%(55/199) vs.12.9%(91/705),χ<sup>2</sup>=30.12,<i>P</i><0.001] and M1 disease [24.6%(49/199) vs. 15.7% (111/705),χ<sup>2</sup>=8.40,<i>P</i>=0.004], and the proportions of patients who received neoadjuvant [79.9% (159/199) vs. 62.3%(439/705), χ<sup>2</sup>=21.54, <i>P</i><0.001] and adjuvant therapy [62.8%(125/199) vs. 50.8% (358/705), χ<sup>2</sup>=9.03, <i>P</i>=0.003] were significantly higher in the EORC group. Mean OS (57.8 vs. 51.9 months; <i>P</i>=0.011) and PFS (53.6 vs. 44.5 months; <i>P</i>=0.001) were also significantly longer in the LORC group. However, after PSM, the intergroup differences in OS and PFS were not significant (<i>P</i>=0.450 and 0.180, respectively). Multivariate Cox regression in the EORC cohort identified carcinoembryonic antigen concentration ≥5 μg/L [hazard ratio (HR), 3.79; 95% confidence interval (CI), 1.34-10.69; <i>P</i>=0.012] and presence of perineural invasion (HR, 7.27; 95%CI, 1.77-29.88; <i>P</i>=0.006) as independent risk factors for overall mortality; the only independent risk factor for cancer progression was carcinoembryonic antigen concentration ≥5 μg/L (HR, 2.56; 95%CI, 1.06-6.17; <i>P</i>=0.037). Restricted cubic spline analysis showed a U-shaped relationship between age and clinical outcome. After PSM, OS and PFS did not show a significant association with age in the < 60 years old group. <b>Conclusion:</b> Compared with LORC, EORC is more likely to be diagnosed at a later stage and has a worse outcome. Early diagnosis and timely treatment improve outcome in EORC patients.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"662-671"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Progress in neoadjuvant immunotherapy for locally advanced rectal cancer]. 局部晚期直肠癌的新辅助免疫治疗进展。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20241114-00373
Y Wang, F Tian, C Q Jing

Neoadjuvant chemoradiotherapy (NACRT) is the standard treatment for locally advanced rectal cancer (LARC), yet the pathological complete response (pCR) rates remain suboptimal. The introduction of immunotherapy has opened new avenues for LARC management, particularly in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status. In this subset, anti-programmed cell death protein-1 (PD-1) monoclonal antibodies demonstrate marked efficacy, achieving high rates of clinical complete response (cCR) and pCR, thereby facilitating non-operative watch-and-wait (W&W) strategies. However, long-term outcomes and large-scale validation are still awaited. Conversely, in patients with LARC who have proficient mismatch repair (pMMR) or microsatellite stability (MSS), PD-1 inhibition alone shows limited benefit. Current research thus focuses on combinatorial approaches. Combining immunotherapy with chemoradiotherapy has shown promise in improving pCR rates in pMMR/MSS LARC, without significantly exacerbating severe adverse events. However, the discordance between post-treatment imaging assessments and pathological findings complicates clinical decision-making. Future directions include optimizing immune checkpoint inhibitor (ICI) regimens for pMMR/MSS LARC, with ongoing investigations into dual immunotherapy and anti-angiogenic synergism. Additionally, biomarker discovery, which is leveraging multi-omics and artificial intelligence (AI), will be pivotal in achieving precision therapy that balances short-term efficacy with long-term survival benefits.

新辅助放化疗(NACRT)是局部晚期直肠癌(LARC)的标准治疗方法,但病理完全缓解(pCR)率仍然不理想。免疫疗法的引入为LARC的管理开辟了新的途径,特别是在错配修复缺陷(dMMR)或微卫星不稳定性高(MSI-H)状态的患者中。在这个亚群中,抗程序性细胞死亡蛋白-1 (PD-1)单克隆抗体表现出显著的疗效,实现了高临床完全缓解率(cCR)和pCR,从而促进了非手术观察和等待(W&W)策略。然而,长期结果和大规模验证仍在等待中。相反,在具有熟练错配修复(pMMR)或微卫星稳定性(MSS)的LARC患者中,单独抑制PD-1的益处有限。因此,目前的研究集中在组合方法上。免疫治疗联合放化疗有望改善pMMR/MSS LARC的pCR率,而不会显著加剧严重不良事件。然而,治疗后影像学评估与病理结果之间的不一致使临床决策复杂化。未来的方向包括优化pMMR/MSS LARC的免疫检查点抑制剂(ICI)方案,以及正在进行的双重免疫治疗和抗血管生成协同作用的研究。此外,利用多组学和人工智能(AI)的生物标志物发现将是实现精确治疗的关键,这将平衡短期疗效和长期生存效益。
{"title":"[Progress in neoadjuvant immunotherapy for locally advanced rectal cancer].","authors":"Y Wang, F Tian, C Q Jing","doi":"10.3760/cma.j.cn441530-20241114-00373","DOIUrl":"10.3760/cma.j.cn441530-20241114-00373","url":null,"abstract":"<p><p>Neoadjuvant chemoradiotherapy (NACRT) is the standard treatment for locally advanced rectal cancer (LARC), yet the pathological complete response (pCR) rates remain suboptimal. The introduction of immunotherapy has opened new avenues for LARC management, particularly in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status. In this subset, anti-programmed cell death protein-1 (PD-1) monoclonal antibodies demonstrate marked efficacy, achieving high rates of clinical complete response (cCR) and pCR, thereby facilitating non-operative watch-and-wait (W&W) strategies. However, long-term outcomes and large-scale validation are still awaited. Conversely, in patients with LARC who have proficient mismatch repair (pMMR) or microsatellite stability (MSS), PD-1 inhibition alone shows limited benefit. Current research thus focuses on combinatorial approaches. Combining immunotherapy with chemoradiotherapy has shown promise in improving pCR rates in pMMR/MSS LARC, without significantly exacerbating severe adverse events. However, the discordance between post-treatment imaging assessments and pathological findings complicates clinical decision-making. Future directions include optimizing immune checkpoint inhibitor (ICI) regimens for pMMR/MSS LARC, with ongoing investigations into dual immunotherapy and anti-angiogenic synergism. Additionally, biomarker discovery, which is leveraging multi-omics and artificial intelligence (AI), will be pivotal in achieving precision therapy that balances short-term efficacy with long-term survival benefits.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"700-706"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial]. [侧端吻合对直肠癌术后肠功能的影响:一项前瞻性单中心随机对照试验]。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250409-00145
C Wang, F Liu, S Hou, Z L Shen, M J Yin, X D Yang, K W Jiang, Q W Xie, B Liang, K Shen, Z D Gao, Y J Ye
<p><p><b>Objective:</b> To compare bowel function 12 months after surgery between side-to-end anastomosis (SEA) and end-to-end anastomosis (EEA) groups of patients who had undergone rectal cancer resection. <b>Methods:</b> This single-center, prospective, open-label, phase III randomized controlled trial was approved by the Ethics Committee of Peking University People's Hospital (2018PHB040-01) and registered at ClinicalTrials. org (NCT03669237). Inclusion criteria were as follows: (1) histologically confirmed rectal adenocarcinoma; (2) tumor located 0 to 12 cm from the anal verge; (3) age≥18 years; and (4) planned R0 resection with primary reconstruction. Exclusion criteria included: (1) emergency surgery; (2) cognitive impairment; (3) non-primary anastomosis; (4) history of left-sided colonic or anorectal surgery; and (5) preexisting chronic defecation dysfunction. Eligible rectal cancer patients scheduled for elective sphincter-preserving surgery at Peking University People's Hospital were prospectively enrolled between October 2018 and March 2021 and randomly assigned to either the EEA group or the SEA group via computer-generated numbers prior to entering the operating room. All patients underwent standard radical tumor resection. Bowel function was evaluated by the low anterior resection syndrome (LARS) questionnaire. It consists of five single-choice questions and yields a total score ranging from 0 to 42. Defecation function is categorized into three levels: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). The primary endpoint was the LARS score 12 months after surgery. Secondary endpoints included LARS scores from 1 to 11 months and during long-term follow-up(>12 months). The final follow-up was completed in July 2022. All randomized patients were included in the intention-to-treat set (ITTS). The full analysis set (FAS) was defined as ITTS patients with valid outcome data. All primary statistical analyses were performed in the FAS, and results were further compared in the per-protocol set (PPS) based on the actual treatment received. <b>Results:</b> A total of 323 patients underwent eligibility assessment, of whom 71 did not meet the inclusion criteria and 52 declined to participate. Ultimately, 200 patients were randomized. Median age was 64 years and 85 were women. The SEA and EEA groups comprised 102 and 98 patients, respectively. A total of 181 patients (90.5%) were included in the FAS, and 170 (85.0%) were included in the PPS. Among these, the 12-month LARS score was evaluated in 178 patients (98.3%) in the FAS and in 167 (98.2%) in the PPS. Median LARS score at 1-12 months were significantly lower in the SEA group in both the FAS dataset [12 months:8 (interquartile range [IQR], 0-22) vs. 14 (IQR, 8-29); <i>Z</i>=2.687, <i>P</i>=0.007] and the PPS dataset [12 months: 8 (IQR, 0-22) vs. 14 (IQR, 6-29); <i>Z</i>=2.543, <i>P</i>=0.011]. During long-term follow-up, the median LARS score was also significa
目的:比较侧端吻合术(SEA)组和端端吻合术(EEA)组直肠癌切除术患者术后12个月的肠功能。方法:该单中心、前瞻性、开放标签、III期随机对照试验经北京大学人民医院伦理委员会批准(2018PHB040-01),并在ClinicalTrials注册。org (NCT03669237)。纳入标准如下:(1)经组织学证实的直肠腺癌;(2)肿瘤位于距肛门边缘0 ~ 12cm处;(3)年龄≥18岁;(4)计划R0切除并一期重建。排除标准包括:(1)急诊手术;(2)认知障碍;(3)非初级吻合;(4)左侧结肠或肛肠手术史;(5)既往慢性排便功能障碍。前瞻性纳入2018年10月至2021年3月在北京大学人民医院择期行保留括约肌手术的符合条件的直肠癌患者,并在进入手术室前通过计算机生成的数字随机分配到EEA组或SEA组。所有患者均行标准根治性肿瘤切除术。通过前低位切除综合征(LARS)问卷评估肠功能。它由五个单项选择题组成,总分在0到42分之间。排便功能分为无LARS(0-20分)、轻度LARS(21-29分)和重度LARS(30-42分)三个级别。主要终点是术后12个月的LARS评分。次要终点包括1 - 11个月和长期随访期间(bb0 - 12个月)的LARS评分。最后的后续工作于2022年7月完成。所有随机患者均纳入意向治疗组(ITTS)。完整分析集(FAS)定义为具有有效结局数据的ITTS患者。所有主要统计分析均在FAS中进行,并根据实际接受的治疗在每个方案集(PPS)中进一步比较结果。结果:共有323例患者接受了资格评估,其中71例不符合纳入标准,52例拒绝参与。最终,200名患者被随机分配。平均年龄为64岁,女性为85岁。SEA组102例,EEA组98例。FAS组181例(90.5%),PPS组170例(85.0%)。其中FAS组178例(98.3%),PPS组167例(98.2%)进行了12个月LARS评分。在FAS数据集中,SEA组在1-12个月时的LARS中位数评分显著低于对照组[12个月:8(四分位间距[IQR], 0-22)比14 (IQR, 8-29);Z=2.687, P=0.007]和PPS数据集[12个月:8 (IQR, 0-22) vs. 14 (IQR, 6-29);Z = 2.543, P = 0.011)。在长期随访期间,FAS数据集中SEA组的LARS中位评分也显著降低[2 (IQR, 0-4) vs. 11 (IQR, 2-23);Z=2.968, P=0.003]和PPS数据集[2 (IQR, 0-14) vs. 11 (2,27)];Z = 2.687, P = 0.007)。结论:与EEA组相比,SEA组术后1年及长期随访期间的肠功能优于EEA组。
{"title":"[Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial].","authors":"C Wang, F Liu, S Hou, Z L Shen, M J Yin, X D Yang, K W Jiang, Q W Xie, B Liang, K Shen, Z D Gao, Y J Ye","doi":"10.3760/cma.j.cn441530-20250409-00145","DOIUrl":"10.3760/cma.j.cn441530-20250409-00145","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To compare bowel function 12 months after surgery between side-to-end anastomosis (SEA) and end-to-end anastomosis (EEA) groups of patients who had undergone rectal cancer resection. &lt;b&gt;Methods:&lt;/b&gt; This single-center, prospective, open-label, phase III randomized controlled trial was approved by the Ethics Committee of Peking University People's Hospital (2018PHB040-01) and registered at ClinicalTrials. org (NCT03669237). Inclusion criteria were as follows: (1) histologically confirmed rectal adenocarcinoma; (2) tumor located 0 to 12 cm from the anal verge; (3) age≥18 years; and (4) planned R0 resection with primary reconstruction. Exclusion criteria included: (1) emergency surgery; (2) cognitive impairment; (3) non-primary anastomosis; (4) history of left-sided colonic or anorectal surgery; and (5) preexisting chronic defecation dysfunction. Eligible rectal cancer patients scheduled for elective sphincter-preserving surgery at Peking University People's Hospital were prospectively enrolled between October 2018 and March 2021 and randomly assigned to either the EEA group or the SEA group via computer-generated numbers prior to entering the operating room. All patients underwent standard radical tumor resection. Bowel function was evaluated by the low anterior resection syndrome (LARS) questionnaire. It consists of five single-choice questions and yields a total score ranging from 0 to 42. Defecation function is categorized into three levels: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). The primary endpoint was the LARS score 12 months after surgery. Secondary endpoints included LARS scores from 1 to 11 months and during long-term follow-up(&gt;12 months). The final follow-up was completed in July 2022. All randomized patients were included in the intention-to-treat set (ITTS). The full analysis set (FAS) was defined as ITTS patients with valid outcome data. All primary statistical analyses were performed in the FAS, and results were further compared in the per-protocol set (PPS) based on the actual treatment received. &lt;b&gt;Results:&lt;/b&gt; A total of 323 patients underwent eligibility assessment, of whom 71 did not meet the inclusion criteria and 52 declined to participate. Ultimately, 200 patients were randomized. Median age was 64 years and 85 were women. The SEA and EEA groups comprised 102 and 98 patients, respectively. A total of 181 patients (90.5%) were included in the FAS, and 170 (85.0%) were included in the PPS. Among these, the 12-month LARS score was evaluated in 178 patients (98.3%) in the FAS and in 167 (98.2%) in the PPS. Median LARS score at 1-12 months were significantly lower in the SEA group in both the FAS dataset [12 months:8 (interquartile range [IQR], 0-22) vs. 14 (IQR, 8-29); &lt;i&gt;Z&lt;/i&gt;=2.687, &lt;i&gt;P&lt;/i&gt;=0.007] and the PPS dataset [12 months: 8 (IQR, 0-22) vs. 14 (IQR, 6-29); &lt;i&gt;Z&lt;/i&gt;=2.543, &lt;i&gt;P&lt;/i&gt;=0.011]. During long-term follow-up, the median LARS score was also significa","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"644-652"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Probiotics empower postoperative intestinal function recovery after colorectal surgery: mechanisms and clinical progress]. [益生菌促进结直肠癌术后肠道功能恢复:机制与临床进展]。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250310-00093
P Lai, Z He

Gastrointestinal dysfunction is a common and significant complication in colorectal surgical practice, which is associated with gut microbiota dysbiosis caused by various perioperative interventions. Currently, enhanced recovery after surgery (ERAS) protocols have been increasingly adopted in clinical practice, greatly accelerating the recovery of postoperative intestinal function. However, there are still no effective interventions in the ERAS protocols to target surgery-induced gut microbiota dysbiosis. Probiotics, as a key treatment method targeting the gut microbiota, can stimulate intestinal motility, inhibit the colonization of pathogenic bacteria, enhance intestinal barrier function, among other effects. Based on these effects of probiotics, they are expected to resolve the neglected gut microbiota dysbiosis, further accelerating the postoperative recovery of intestinal function after colorectal surgery. This article reviews the mechanisms and clinical progress in postoperative bowel functional recovery after colorectal surgery.

胃肠功能障碍是结直肠手术中常见且重要的并发症,它与各种围手术期干预引起的肠道菌群失调有关。目前,临床越来越多地采用ERAS (enhanced recovery after surgery)方案,大大加快了术后肠道功能的恢复。然而,在ERAS方案中仍然没有针对手术引起的肠道菌群失调的有效干预措施。益生菌作为针对肠道菌群的关键治疗手段,具有刺激肠道蠕动、抑制病原菌定植、增强肠道屏障功能等作用。基于益生菌的这些作用,它们有望解决被忽视的肠道菌群失调,进一步加速结肠直肠癌术后肠道功能的恢复。本文就结直肠手术后肠功能恢复的机制及临床进展进行综述。
{"title":"[Probiotics empower postoperative intestinal function recovery after colorectal surgery: mechanisms and clinical progress].","authors":"P Lai, Z He","doi":"10.3760/cma.j.cn441530-20250310-00093","DOIUrl":"10.3760/cma.j.cn441530-20250310-00093","url":null,"abstract":"<p><p>Gastrointestinal dysfunction is a common and significant complication in colorectal surgical practice, which is associated with gut microbiota dysbiosis caused by various perioperative interventions. Currently, enhanced recovery after surgery (ERAS) protocols have been increasingly adopted in clinical practice, greatly accelerating the recovery of postoperative intestinal function. However, there are still no effective interventions in the ERAS protocols to target surgery-induced gut microbiota dysbiosis. Probiotics, as a key treatment method targeting the gut microbiota, can stimulate intestinal motility, inhibit the colonization of pathogenic bacteria, enhance intestinal barrier function, among other effects. Based on these effects of probiotics, they are expected to resolve the neglected gut microbiota dysbiosis, further accelerating the postoperative recovery of intestinal function after colorectal surgery. This article reviews the mechanisms and clinical progress in postoperative bowel functional recovery after colorectal surgery.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"619-626"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Interpretation of the update points of colorectal and anal cancer in CACA guidelines (2025 edition)]. 【CACA指南(2025年版)结直肠癌和肛门癌更新点解读】。
Q3 Medicine Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn441530-20250306-00087
Z J Guan, W Y Zhang, G Y Wang

The key points of the update of the content related to colorectal cancer and anal cancer in the Chinese Anti-Cancer Association (CACA) Guidelines for Integrative Oncology 2025 Edition (hereinafter referred to as the CACA 2025 Guidelines) include 4 aspects. In terms of epidemiology, the latest data on the incidence and mortality of colorectal cancer in China have been updated, and the recommended screening age has been adjusted. In diagnosis, the application of enhanced MRI examination in diagnosis has been optimized, and the recommendation for peripheral blood microsatellite instability (MSI) detection has been added. In terms of treatment, in surgical treatment, the total mesorectal excision of the right colon, the safety of the Natural Orifice Specimen Extraction Surgery (NOSES) technique, the applicable range of robotic surgery, and the high-level evidence-based medical evidence of transanal total mesorectal excision (taTME) have been newly added, and the principles of surgical treatment have been added as well. In medical treatment, the role of circulating tumor DNA (ctDNA) in treatment decision-making has been supplemented. The application of dual immunotherapy in advanced patients has been recommended, and the application of third-line and subsequent-line treatments in advanced patients has been newly added. The guidelines improved the principle of preoperative neoadjuvant radiotherapy for rectal cancer, changed the indication of short-course radiotherapy, and added a variety of chemoradiotherapy combinations and recommendations for the timing of surgery. In addition, the follow-up programs for colorectal cancer and anal canal cancer are clarified, and nutritional therapy, traditional Chinese medicine rehabilitation therapy and nursing care for sequelae are emphasized, which provide more scientific and comprehensive guidance for the diagnosis and treatment of colorectal cancer and anal canal cancer.

中国抗癌协会(CACA)《综合肿瘤学指南2025版》(以下简称《CACA指南2025》)中大肠癌和肛门癌相关内容的更新重点包括4个方面。在流行病学方面,更新了中国结直肠癌发病率和死亡率的最新数据,并调整了推荐筛查年龄。在诊断方面,优化了MRI增强检查在诊断中的应用,增加了外周血微卫星不稳定性(MSI)检测的推荐。在治疗方面,在手术治疗方面,新增了右结肠直肠全系膜切除术、自然口标本提取术(nose)技术的安全性、机器人手术的适用范围、经肛门直肠全系膜切除术(taTME)的高水平循证医学证据,并增加了手术治疗原则。在医学治疗中,循环肿瘤DNA (ctDNA)在治疗决策中的作用得到了补充。建议在晚期患者中应用双重免疫治疗,并新增了三线及后续治疗在晚期患者中的应用。该指南完善了直肠癌术前新辅助放疗的原则,改变了短程放疗的适应症,增加了多种放化疗组合和手术时机的建议。此外,明确了结直肠癌、肛管癌的随访方案,强调了营养治疗、中医康复治疗、后遗症护理等,为结直肠癌、肛管癌的诊治提供了更加科学、全面的指导。
{"title":"[Interpretation of the update points of colorectal and anal cancer in CACA guidelines (2025 edition)].","authors":"Z J Guan, W Y Zhang, G Y Wang","doi":"10.3760/cma.j.cn441530-20250306-00087","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20250306-00087","url":null,"abstract":"<p><p>The key points of the update of the content related to colorectal cancer and anal cancer in the Chinese Anti-Cancer Association (CACA) Guidelines for Integrative Oncology 2025 Edition (hereinafter referred to as the CACA 2025 Guidelines) include 4 aspects. In terms of epidemiology, the latest data on the incidence and mortality of colorectal cancer in China have been updated, and the recommended screening age has been adjusted. In diagnosis, the application of enhanced MRI examination in diagnosis has been optimized, and the recommendation for peripheral blood microsatellite instability (MSI) detection has been added. In terms of treatment, in surgical treatment, the total mesorectal excision of the right colon, the safety of the Natural Orifice Specimen Extraction Surgery (NOSES) technique, the applicable range of robotic surgery, and the high-level evidence-based medical evidence of transanal total mesorectal excision (taTME) have been newly added, and the principles of surgical treatment have been added as well. In medical treatment, the role of circulating tumor DNA (ctDNA) in treatment decision-making has been supplemented. The application of dual immunotherapy in advanced patients has been recommended, and the application of third-line and subsequent-line treatments in advanced patients has been newly added. The guidelines improved the principle of preoperative neoadjuvant radiotherapy for rectal cancer, changed the indication of short-course radiotherapy, and added a variety of chemoradiotherapy combinations and recommendations for the timing of surgery. In addition, the follow-up programs for colorectal cancer and anal canal cancer are clarified, and nutritional therapy, traditional Chinese medicine rehabilitation therapy and nursing care for sequelae are emphasized, which provide more scientific and comprehensive guidance for the diagnosis and treatment of colorectal cancer and anal canal cancer.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"693-699"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华胃肠外科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1